dTMS as a Treatment for Patients With Fibromyalgia

Inclusion Criteria: * Age: 18-80 years. * Patients who continue to take their administered medications or patients who stopped ineffective administered medications * Concomitant medication for pain and sleep disorders will be allowed provided the dose administered had been stable for at least 2 weeks before enrollment and remains stable throughout the study. * Gave informed consent for participation in the study. Exclusion Criteria: * Subjects will be excluded if evidence is found of inflammatory rheumatic disease, autoimmune disease, or other painful disorders that might confound assessment of FMS pain. * Subjects diagnosed with a current primary (Axis I) psychiatric condition according to Diagnostic and Statistical Manual of Mental Disorders-IV criteria, including anxiety disorders, not including major depression or major personality disorder. Subject with a history of substance abuse and pregnant women will be excluded as well. * History of any metal in the head (outside the mouth). * Known history of any metallic particles in the eye, implanted cardiac pacemaker or any intracardiac lines, implanted neurostimulators, surgical clips or any medical pumps. * History of head injury. * History of seizure or heat convulsion. * History of epilepsy or seizure in first degree relatives. * History of frequent or severe headaches. * Use of hearing aids for hearing loss. * Known history of cochlear implants. * History of drug abuse or alcoholism during the last year. * Serious and unstable medical condition, which is likely to exacerbate or endanger the patient during the treatment period. * Significant difficulties in language or communication. * Subjects declared as legally incompetent, with an appointed physical guardian and/or cannot sign informed consent due to cognitive incompetence. * Participation in current clinical study or clinical study within 30 days prior to this study.